Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVHNLC Plus Pembrolizumab in sqNSCLC
NCT07073183Phase 1Withdrawn
- Sponsor
- CureVac
- Start
- Jul 2025
- Primary completion
- Dec 2029
- Modality
- Vaccine mRNA, mRNA Vaccines
- Countries
- 3
01
Overview
Phase 1, open-label trial of CV09070101 in squamous cell carcinoma of the lung (SCCL) (5 arms), sponsored by CureVac. Primary endpoints: Incidence of treatment-related adverse events at 1 year, Incidence of treatment-emergent adverse events at 1 year and 7 more. Planned start Jul 2025; status: withdrawn.
02
Drugs
CV09070101
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07073183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073183.